Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Part of paid clinical trials in Decatur, Illinois.

Sponsor
Wake Forest University Health Sciences
Study ID
NCT00025285
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining thalidomide with chemotherapy may kill more tumor cells and be an effective treatment for stage IIIB or stage IV non-small cell lung cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus thalidomide in treating patients who have stage IIIB or stage IV non-small cell lung cancer.

Key Dates

Start date
Nov 1, 2001
Status verified
Sep 2021
Primary completion
Sep 29, 2004
Completion
Sep 29, 2004

Study Design

Enrollment
46 participants (actual)
Primary purpose
TREATMENT

Locations (5)

FacilityCityStateZIPSite coordinators
CCOP - Central IllinoisDecaturIllinois62526-
Southeastern Medical Oncology CenterGoldsboroNorth Carolina27534-9479-
Comprehensive Cancer Center at Wake Forest UniversityWinston-SalemNorth Carolina27157-1082-
CCOP - GreenvilleGreenvilleSouth Carolina29615-
CCOP - Upstate CarolinaSpartanburgSouth Carolina29303-

Find similar trials in Decatur, IL

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
CCOP - Central Illinois· Decatur, ILSoutheastern Medical Oncology Center· Goldsboro, NCComprehensive Cancer Center at Wake Forest University· Winston-Salem, NCCCOP - Greenville· Greenville, SCCCOP - Upstate Carolina· Spartanburg, SC

Related Studies